NCT03085849 - SGI-110 Plus Durvalumab/Tremelimumab in SCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

November 26, 2018

Study Completion Date

November 26, 2018

Conditions

Extensive-stage Small Cell Lung Cancer

Interventions

DRUG

Durvalumab

1500 mg IV on day 8 (flat dose) until progression

DRUG

Tremelimumab

75 mg IV on day 8 (flat dose) x 4 doses

DRUG

SGI-110

"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors

lead

Catherine Shu

OTHER